Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab plus carboplatin-pemetrexed vs carboplatin-pemetrexed in EGFR Exon 20ins NSCLC
NCT04538664Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2020
- Primary completion
- May 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 26
01
Overview
A Phase 3 trial of amivantamab in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Oct 2020; status: active, not recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04538664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04538664.